Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 ―― ...

Fulcrum Therapeutics (NASDAQ:FULC) lost ~70% premarket Thursday after its lead program for protein kinase inhibitor, ...

BofA Securities has upgraded Fulcrum Therapeutics (NASDAQ:FULC) ahead of the company’s phase 3 losmapimod readout, expected ...

Fulcrum is developing another pipeline candidate, pociredir, in an early-stage study for treating patients with sickle cell ...

In a report released on September 11, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Fulcrum Therapeutics (FULC – ...

WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with ...

Investing in biotech stocks can be risky, particularly in the clinical stage, since their success often hinges on the results ...

FSHD is a genetic disorder that causes muscle weakness and wasting in the face, shoulder blades and upper arms. The estimated ...

Shares of Fulcrum Therapeutics plummeted after the company said a trial evaluating losmapimod as a treatment for facioscapulohumeral muscular dystrophy missed its primary endpoint. The stock was down ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.0, a high estimate of $23.00, ...

Fulcrum Therapeutics, Inc. stock plunged 60% as lead candidate failed its Phase 3 trial. Is this a contrarian opportunity?

The S&P 500's 2024 rally continued in July as second-quarter GDP growth numbers exceeded expectations. Investors also expect Federal Reserve rate cuts are now just around the corner. The S& ...